Physician profile
Deborah Hackett
NPI 1699434274
$9,112.80
in general payments reported to CMS, 2019-2025
48 companies · $1,560 in 2025
The $1,560 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,676 · 2023: $3,374 · 2024: $2,503 · 2025: $1,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,435 · Education: $2.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,434.50 |
| Education | $2.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,480.82 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $1,238.22 | 2022-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $838.86 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novo Nordisk INC | $685.93 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $664.16 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Regeneron Healthcare Solutions, INC. | $538.30 | 2023-2025 | Dupixent |
| Pfizer INC. | $335.64 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.13 | 2022-2024 | Jardiance, Stiolto Respimat |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $180.16 | 2022-2024 | Caplyta |
| Biocryst US Sales Co., LLC | $160.94 | 2024-2025 | Orladeyo |
| Biohaven Pharmaceutical Holding Company Ltd. | $156.73 | 2022 | |
| Novartis Pharmaceuticals Corporation | $152.44 | 2025 | |
| Halozyme INC | $144.63 | 2023 | |
| Optinose US, INC. | $125.54 | 2024-2025 | |
| Genzyme Corporation | $119.80 | 2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $116.04 | 2022-2023 | Eliquis |
| Idorsia Pharmaceuticals US INC | $115.45 | 2023-2024 | Quviviq |
| Impel Pharmaceuticals INC. | $111.23 | 2023 | Trudhesa |
| Antares Pharma, INC. | $108.24 | 2023 | Nocdurna, Xyosted, Tlando |
| Corium, LLC | $100.06 | 2023-2024 | Azstarys |
| Collegium Pharmaceutical, INC. | $97.62 | 2022-2023 | Xtampza, Belbuca |
| Amgen INC. | $95.87 | 2022-2024 | Prolia, Evenity |
| Kowa Pharmaceuticals America, INC. | $93.43 | 2022-2025 | Zoryve, Livalo, Seglentis |
| Paratek Pharmaceuticals, INC. | $93.41 | 2022-2023 | Nuzyra |
| Exact Sciences Corporation | $86.31 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $82.60 | 2022-2023 | |
| Ars Pharmaceuticals Operations, INC. | $78.47 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $75.24 | 2023-2025 | Trintellix, Cuvitru, Takhzyro |
| Amarin Pharma, INC. | $67.67 | 2022-2023 | |
| Braeburn INC. | $62.37 | 2023-2024 | Brixadi |
| Greer Laboratories, INC. | $57.99 | 2024-2025 | Palforzia |
| Teva Pharmaceuticals USA, INC. | $55.68 | 2022-2023 | Austedo Xr, Austedo |
| Sumitomo Pharma America, INC. | $54.56 | 2023 | Gemtesa |
| Lundbeck LLC | $52.49 | 2024 | Rexulti |
| Scilex Pharmaceuticals INC. | $44.62 | 2022-2023 | Ztlido |
| Abbott Laboratories | $42.89 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $37.89 | 2022-2023 | Belsomra |
| Csl Behring | $32.13 | 2025 | Hizentra |
| Inspire Medical Systems, INC. | $30.00 | 2024 | Inspire |
| Otsuka America Pharmaceutical, INC. | $24.67 | 2023 | Jynarque |
| Corcept Therapeutics | $23.68 | 2023 | Korlym |
| Indivior INC. | $23.28 | 2023 | Sublocade |
| Phathom Pharmaceuticals, INC. | $18.14 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.03 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.88 | 2023 | Edarbyclor |
| Currax Pharmaceuticals LLC | $16.76 | 2022 | |
| Philips North America LLC | $16.67 | 2023 | |
| Galderma Laboratories, L.P. | $14.13 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Hackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.